trending Market Intelligence /marketintelligence/en/news-insights/trending/3wamugze_smfvb3nk82vbg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

FDA Watch: Approval for Johnson & Johnson; designations for Neovasc, Iovance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

FDA Watch: Approval for Johnson & Johnson; designations for Neovasc, Iovance

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Oct. 12.


* Johnson & Johnson's Xarelto, in combination with aspirin, to treat patients with coronary artery disease or peripheral arterial disease.

* Grifols SA's ID CORE XT, a test to determine blood compatibility for transfusions.

* Akorn Inc.'s bimatoprost ophthalmic solution, for hypotrichosis.

* Bausch Health Cos. Inc.'s Bryhali lotion, for adults with plaque psoriasis. The FDA granted tentative approval to Bausch Health.

SNL Image
FDA headquarters in Silver Spring, Md.
Source: Associated Press

Complete response letters

* TearLab Corp.'s TearLab Discovery MMP-9 test, which helps diagnose dry eye disease. The FDA said the data in TearLab's regulatory submission has not met the criteria for substantial equivalence.

Breakthrough therapy

* Neovasc Inc.'s Reducer chest pain device, for patients with refractory angina.

Other designations

* Regenerative medicine advanced therapy, for Iovance Biotherapeutics Inc.'s lifileucel, to treat advanced melanoma.

* Orphan drug, for Sutro Biopharma Inc.'s STRO-001, to treat multiple myeloma.

* Qualified infectious disease product, for Spero Therapeutics Inc.'s SPR206, to treat urinary tract infections, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.